🚀 VC round data is live in beta, check it out!
Palisade Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Palisade Bio and similar public comparables like Oryzon Genomics, Journey Medical, Satellos Bioscience, ALX Oncology and more.
Palisade Bio Overview
About Palisade Bio
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Founded
2001
HQ
Employees
8
Website
Sectors
Financials (LTM)
EV
$265M
Palisade Bio Financials
Palisade Bio reported last 12-month revenue of —.
In the same LTM period, Palisade Bio generated — in gross profit and had net loss of ($20M).
Revenue (LTM)
Palisade Bio P&L
In the most recent fiscal year, Palisade Bio reported revenue of — and EBITDA of ($17M).
Palisade Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($17M) | XXX | XXX | XXX |
| Net Profit | ($20M) | XXX | ($14M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Palisade Bio Stock Performance
Palisade Bio has current market cap of $270M, and enterprise value of $265M.
Market Cap Evolution
Palisade Bio's stock price is $1.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $265M | $270M | 0.0% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPalisade Bio Valuation Multiples
Palisade Bio trades at (15.8x) EV/EBITDA.
EV / Revenue (LTM)
Palisade Bio Financial Valuation Multiples
As of March 29, 2026, Palisade Bio has market cap of $270M and EV of $265M.
Equity research analysts estimate Palisade Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Palisade Bio has a P/E ratio of (13.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $270M | XXX | $270M | XXX | XXX | XXX |
| EV (current) | $265M | XXX | $265M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (15.8x) | XXX | XXX | XXX |
| EV/EBIT | (12.5x) | XXX | (18.8x) | XXX | XXX | XXX |
| P/E | (13.3x) | XXX | (20.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (24.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Palisade Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Palisade Bio Margins & Growth Rates
Palisade Bio's revenue in the last fiscal year declined by (100%).
Palisade Bio's revenue per employee in the last FY averaged $0.0M.
Palisade Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Palisade Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Journey Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Satellos Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| ALX Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Abeona Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Palisade Bio M&A Activity
Palisade Bio acquired XXX companies to date.
Last acquisition by Palisade Bio was on XXXXXXXX, XXXXX. Palisade Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Palisade Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPalisade Bio Investment Activity
Palisade Bio invested in XXX companies to date.
Palisade Bio made its latest investment on XXXXXXXX, XXXXX. Palisade Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Palisade Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Palisade Bio
| When was Palisade Bio founded? | Palisade Bio was founded in 2001. |
| Where is Palisade Bio headquartered? | Palisade Bio is headquartered in United States. |
| How many employees does Palisade Bio have? | As of today, Palisade Bio has over 8 employees. |
| Is Palisade Bio publicly listed? | Yes, Palisade Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Palisade Bio? | Palisade Bio trades under PALI ticker. |
| When did Palisade Bio go public? | Palisade Bio went public in 2021. |
| Who are competitors of Palisade Bio? | Palisade Bio main competitors are Oryzon Genomics, Journey Medical, Satellos Bioscience, ALX Oncology. |
| What is the current market cap of Palisade Bio? | Palisade Bio's current market cap is $270M. |
| Is Palisade Bio profitable? | No, Palisade Bio is not profitable. |
| What is the current net income of Palisade Bio? | Palisade Bio's last 12 months net income is ($20M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.